Last reviewed · How we verify
acoltremon 0.003%
Acoltremon is a topical retinoid that modulates retinoid receptor signaling to promote corneal epithelial healing and reduce inflammation.
Acoltremon is a topical retinoid that modulates retinoid receptor signaling to promote corneal epithelial healing and reduce inflammation. Used for Dry eye disease (marketed formulation).
At a glance
| Generic name | acoltremon 0.003% |
|---|---|
| Sponsor | Center for Sight Las Vegas |
| Drug class | Retinoid |
| Target | Retinoid receptors (RAR/RXR) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
As a retinoid compound applied topically at 0.003% concentration, acoltremon activates retinoid receptors in ocular tissues, which enhances epithelial cell differentiation and proliferation while reducing inflammatory responses. This mechanism supports corneal surface repair and may improve symptoms associated with dry eye disease or other anterior segment conditions.
Approved indications
- Dry eye disease (marketed formulation)
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Transient vision blurring
Key clinical trials
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
- A Study Designed to Evaluate Tear Production (PHASE3)
- Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome (PHASE4)
- Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) (PHASE4)
- Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon
- Switching From Restasis to TRYPTYR (PHASE4)
- Switching From Xiidra to TRYPTYR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- acoltremon 0.003% CI brief — competitive landscape report
- acoltremon 0.003% updates RSS · CI watch RSS
- Center for Sight Las Vegas portfolio CI